VHIR is a public-sector institution that promotes and develops the research, innovation and biosanitary teaching of the Vall d’Hebron University Hospital inside Vall d’Hebron Barcelona Hospital Campus. Through the excellence of their research, they identify and apply new solutions to the health problems of society contributing to spread them around the world.
The Pediatric Neurology Research group is mainly involved in the study of genetic diseases of the developing nervous system. The main emphasis is on paroxysmal neurological disorders and neuromuscular disorders. A common theme across the different projects, besides the identification of the molecular basis of several of these rare disorders, is the investigation of molecules involved in their pathophysiological mechanisms and the effective translation of these findings into the fields of molecular diagnosis, genetic counselling and newly developed gene or drug therapies.
The Group for Translational Research into Childhood and Adolescent Cancer is focused on research for new treatment targets or molecule targets (the place in the organism a drug acts on), based on the most advanced knowledge available on the biology of paediatric cancers. The Group has identified and will continue to work on new molecular targets for sarcomas (cancer that originates in connective tissue cells) and tumours of the nervous system. The group applies the knowledge acquired from basic research to the prevention and treatment of clinical cases in childhood cancer and haematological diseases, which contributes to better diagnosis, prognosis, treatment and control of such diseases
Dedicated to paediatric research. Interested in rare respiratory and endocrinologic diseases, but also in common paediatric problems like growth in normal children, asthma, neonatal problems and imaging. The research in rare diseases is focused on identifying genetic mutations, and understanding how these mutations adversely affect the activity of cells that ultimately result in rare diseases. For patients and families suffering these disorders is very important to have a correct diagnosis. Improving diagnosis and creating new tools should allow genomic testing to become part of National Health Service healthcare and will help identify patients suitable for treatment with new therapies.
The Cardiac Surgery and Pediatric Cardiology Service of Vall d’Hebron has participated in more than one hundred research projects. Among the research carried out are the study of the neurological repercussions of fetuses and newborns with congenital heart disease; new cardiac surgery techniques; the program in interventional and pediatric hemodynamics with the use of new devices for percutaneous treatment; the development of new drugs for heart failure and severe pulmonary arterial hypertension and of new ventricular assist devices for treatment bridging cardiac transplantation; the creation of a home monitoring system for children with heart disease and the development of new imaging techniques with cardiac echocardiography. In addition, in the field of genetic studies, the service participate in international research on hereditary diseases of the aorta and hereditary heart diseases with risk of sudden death.
The HIV Translational Laboratory is focused on the characterization of the latent HIV reservoir and the development of new therapeutic strategies directed to deplete this latent reservoir with the ultimate goal of curing HIV. The lab is located within the Infectious Disease unit of the Vall d´Hebrón Hospital, and has access to clinical samples of more than 2100 HIV-infected patients. The priority research lines are: i) Understanding the viral mechanisms involved in the long-term maintenance of viral latency, ii) Assessing the impact of new drugs to purge the latent reservoir, iii) Exploring new synergistic approaches to deplete the latent reservoir with bi-specific nanoparticles, and iv) Targeting specific sites of viral replication. Moreover, we are working with samples from SARS-CoV-2 infected patients in two different lines of research: i) identification of repurposing drugs using lung tissue models, and ii) predicting long-term immunity.